Identification of CKD, bedridden history and cancer as higher-risk comorbidities and their impact on prognosis of hospitalized Omicron patients: a multi-centre cohort study

References

• Weekly epidemiological update on COVID-19 – 3 August 2022. [cited 2022 Aug 9]. https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19—3-august-2022
   Google Scholar
• World Health Organization. Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern. [cited 2022 June 12]. https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern.
   Google Scholar
• Butt AA, Dargham SR, Loka S, et al. COVID-19 disease severity in children infected with the Omicron variant. Clin Infect Dis. 2022;75(1):e361–e367.
   PubMed Web of Science ®Google Scholar
• Fan Y, Li X, Zhang L, et al. SARS-CoV-2 Omicron variant: recent progress and future perspectives. Signal Transduct Target Ther. 2022;7:141.
   PubMed Web of Science ®Google Scholar
• Menni C, Valdes AM, Polidori L, et al. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID study. Lancet. 2022;399:1618–1624.
   PubMed Web of Science ®Google Scholar
• Tiecco G, Storti S, Degli Antoni M, et al. Omicron genetic and clinical peculiarities that may overturn SARS-CoV-2 pandemic: a literature review. Int J Mol Sci. 2022;23:1987.
   PubMed Web of Science ®Google Scholar
• Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet. 2020;395:1054–1062.
   PubMed Web of Science ®Google Scholar
• Christensen PA, Olsen RJ, Long SW, et al. Signals of significantly increased vaccine breakthrough, decreased hospitalization rates, and less severe disease in patients with coronavirus disease 2019 caused by the Omicron variant of severe acute respiratory syndrome Coronavirus 2 in Houston, Texas. Am J Pathol. 2022;192:642–652.
   PubMed Web of Science ®Google Scholar
• Bhatraju PK, Ghassemieh BJ, Nichols M, et al. Covid-19 in critically ill patients in the Seattle Region – case series. N Engl J Med. 2020;382:2012–2022.
   PubMed Web of Science ®Google Scholar
• Cai Q, Chen F, Wang T, et al. Obesity and COVID-19 severity in a designated hospital in Shenzhen, China. Diabetes Care. 2020;43:1392–1398.
   PubMed Web of Science ®Google Scholar
• Stefan N, Birkenfeld AL, Schulze MB, et al. Obesity and impaired metabolic health in patients with COVID-19. Nat Rev Endocrinol. 2020;16:341–342.
   PubMed Web of Science ®Google Scholar
• Solera JT, Árbol BG, Alshahrani A, et al. Impact of vaccination and early monoclonal antibody therapy on COVID-19 outcomes in organ transplant recipients during the Omicron wave. Clin Infect Dis. 2022:ciac324.
   PubMedGoogle Scholar
• Yonekawa A, Shimono N. Clinical significance of COVID-19 and diabetes: in the pandemic situation of SARS-CoV-2 variants including Omicron (B.1.1.529). Biology (Basel). 2022;11:400.
   PubMedGoogle Scholar
• Cornberg M, Buti M, Eberhardt CS, et al. EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients. J Hepatol. 2021;74:944–951.
   PubMed Web of Science ®Google Scholar
• Kompaniyets L, Pennington AF, Goodman AB, et al. Underlying medical conditions and severe illness among 540,667 adults hospitalized with COVID-19, March 2020–March 2021. Prev Chronic Dis. 2021;18:E66.
   PubMed Web of Science ®Google Scholar
• Kahn F, Bonander C, Moghaddassi M, et al. Risk of severe COVID-19 from the Delta and Omicron variants in relation to vaccination status, sex, age and comorbidities – surveillance results from southern Sweden, July 2021 to January 2022. Euro Surveill. 2022;27; doi:10.2807/1560-7917.ES.2022.27.9.2200121.
   Google Scholar
• Ahmad FB, Cisewski JA, Miniño A, et al. Provisional mortality data – United States, 2020. MMWR Morb Mortal Wkly Rep. 2021;70:519–522.
   PubMedGoogle Scholar
• Pennington AF, Kompaniyets L, Summers AD, et al. Risk of clinical severity by age and race/ethnicity among adults hospitalized for COVID-19-United States, March–September 2020. Open Forum Infect Dis. 2021;8:ofaa638.
   PubMed Web of Science ®Google Scholar
• Report 50 – Hospitalisation risk for Omicron cases in England. Imperial College London. [cited 2022 Jun 12]. https://www.imperial.ac.uk/medicine/departments/school-public-health/infectious-disease-epidemiology/mrc-global-infectious-disease-analysis/covid-19/report-50-severity-omicron/.
   Google Scholar
• Ma A, Parry J. When Hong Kong’s ‘dynamic zero’ covid-19 strategy met omicron, low vaccination rates sent deaths soaring. BMJ. 2022;377:o980.
   PubMedGoogle Scholar
• Modes ME, Directo MP, Melgar M, et al. Clinical characteristics and outcomes among adults hospitalized with laboratory-confirmed SARS-CoV-2 infection during periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) variant predominance – One Hospital, California, July 15-September 23, 2021, and December 21, 2021-January 27, 2022. MMWR Morb Mortal Wkly Rep. 2022;71:217–223.
   PubMedGoogle Scholar
• Agarwal A, Rochwerg B, Lamontagne F, et al. A living WHO guideline on drugs for covid-19. BMJ. 2020;370:m3379.
   PubMedGoogle Scholar
• Bakouny Z, Hawley JE, Choueiri TK, et al. COVID-19 and cancer: current challenges and perspectives. Cancer Cell. 2020;38:629–646.
   PubMed Web of Science ®Google Scholar
• Chung EYM, Palmer SC, Natale P, et al. Incidence and outcomes of COVID-19 in people with CKD: a systematic review and meta-analysis. Am J Kidney Dis. 2021;78:804–815.
   PubMed Web of Science ®Google Scholar
• ERA-EDTA Council, ERACODA Working Group. Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA. Nephrol Dial Transplant. 2021;36:87–94.
   PubMed Web of Science ®Google Scholar
• Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584:430–436.
   PubMed Web of Science ®Google Scholar
• Callender LA, Curran M, Bates SM, et al. The impact of pre-existing comorbidities and therapeutic interventions on COVID-19. Front Immunol. 2020;11:1991.
   PubMed Web of Science ®Google Scholar
• D’Marco L, Puchades MJ., Romero-Parra M et al. Coronavirus disease 2019 in chronic kidney disease. Clin Kidney J. 2020;13:297–306.
   PubMed Web of Science ®Google Scholar
• Azevedo RB, Botelho BG, Hollanda Jde, et al. Covid-19 and the cardiovascular system: a comprehensive review. J Hum Hypertens. 2021;35:4–11.
   PubMed Web of Science ®Google Scholar
• Iio R, Kaneko T, Mizuno H, et al. Clinical characteristics of COVID-19 infection in a dialysis center during a nosocomial outbreak. Clin Exp Nephrol. 2021;25:652–659.
   PubMed Web of Science ®Google Scholar
• Anker MS, Landmesser U, von Haehling S, et al. Weight loss, malnutrition, and cachexia in COVID-19: facts and numbers. J Cachexia Sarcopenia Muscle. 2021;12:9–13.
   PubMed Web of Science ®Google Scholar
• Goldman JD, Robinson PC, Uldrick TS, et al. COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies. J Immunother Cancer. 2021;9:e002630.
   PubMed Web of Science ®Google Scholar
• Tian Y, Qiu X, Wang C, et al. Cancer associates with risk and severe events of COVID-19: A systematic review and meta-analysis. Int J Cancer. 2021;148:363–374.
   PubMed Web of Science ®Google Scholar
• Tian J, Yuan X, Xiao J, et al. Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study. Lancet Oncol. 2020;21:893–903.
   PubMed Web of Science ®Google Scholar
• Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378:158–168.
   PubMed Web of Science ®Google Scholar
• Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020;20:651–668.
   PubMed Web of Science ®Google Scholar
• Pedreañez A, Mosquera-Sulbaran J, Muñoz N. SARS-CoV-2 infection represents a high risk for the elderly: analysis of pathogenesis. Arch Virol. 2021;166:1565–1574.
   PubMed Web of Science ®Google Scholar
• Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ. 2021;373:n1088.
   PubMed Web of Science ®Google Scholar
• Al Kaabi N, Oulhaj A, Al Hosani FI, et al. The incidence of COVID-19 infection following emergency use authorization of BBIBP-CORV inactivated vaccine in frontline workers in the United Arab Emirates. Sci Rep. 2022;12:490.
   PubMed Web of Science ®Google Scholar
• Sanders J-SF, Bemelman FJ, Messchendorp AL, et al. The RECOVAC immune-response study: the immunogenicity, tolerability, and safety of COVID-19 vaccination in patients with chronic kidney disease, on dialysis, or living with a kidney transplant. Transplantation. 2022;106:821–834.
   PubMed Web of Science ®Google Scholar